Cargando…

The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy

INTRODUCTION: Cisplatin is used as treatment for several different malignancies and a well-known complication is irreversible kidney damage. To protect the kidneys, this treatment is often combined with mannitol infusion to promote osmotic diuresis. Earlier studies investigating the nephroprotective...

Descripción completa

Detalles Bibliográficos
Autores principales: Hägerström, Erik, Lindberg, Lotte, Bentzen, Jens, Brødbæk, Kasper, Zerahn, Bo, Kristensen, Bent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327333/
https://www.ncbi.nlm.nih.gov/pubmed/30670924
http://dx.doi.org/10.1177/1179554918821320
_version_ 1783386447323070464
author Hägerström, Erik
Lindberg, Lotte
Bentzen, Jens
Brødbæk, Kasper
Zerahn, Bo
Kristensen, Bent
author_facet Hägerström, Erik
Lindberg, Lotte
Bentzen, Jens
Brødbæk, Kasper
Zerahn, Bo
Kristensen, Bent
author_sort Hägerström, Erik
collection PubMed
description INTRODUCTION: Cisplatin is used as treatment for several different malignancies and a well-known complication is irreversible kidney damage. To protect the kidneys, this treatment is often combined with mannitol infusion to promote osmotic diuresis. Earlier studies investigating the nephroprotective effect of mannitol have shown conflicting results. OBJECTIVE: To investigate changes in kidney function in head and neck cancer patients treated with cisplatin with and without additional mannitol infusion. METHODS: A single center, retrospective cohort study of patients with squamous cell carcinoma of the head and neck receiving radiotherapy with cisplatin. Patient data were collected from November 2013 to December 2014. RESULTS: After exclusion, a total of 78 patients were considered evaluable. They were equally distributed between a mannitol and a non-mannitol group and anthropomorphometrically similar. (51)Cr-EDTA clearance declined in the mannitol group from 99.7 (19.9) to 96.4 (20.8) mL/min and in the non-mannitol group from 102.2 (17.8) to 92.3 (23.1) mL/min. CONCLUSIONS: There was a significantly smaller decrease in (51)Cr-EDTA clearance in the mannitol group indicating a nephroprotective effect of mannitol.
format Online
Article
Text
id pubmed-6327333
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-63273332019-01-22 The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy Hägerström, Erik Lindberg, Lotte Bentzen, Jens Brødbæk, Kasper Zerahn, Bo Kristensen, Bent Clin Med Insights Oncol Original Research INTRODUCTION: Cisplatin is used as treatment for several different malignancies and a well-known complication is irreversible kidney damage. To protect the kidneys, this treatment is often combined with mannitol infusion to promote osmotic diuresis. Earlier studies investigating the nephroprotective effect of mannitol have shown conflicting results. OBJECTIVE: To investigate changes in kidney function in head and neck cancer patients treated with cisplatin with and without additional mannitol infusion. METHODS: A single center, retrospective cohort study of patients with squamous cell carcinoma of the head and neck receiving radiotherapy with cisplatin. Patient data were collected from November 2013 to December 2014. RESULTS: After exclusion, a total of 78 patients were considered evaluable. They were equally distributed between a mannitol and a non-mannitol group and anthropomorphometrically similar. (51)Cr-EDTA clearance declined in the mannitol group from 99.7 (19.9) to 96.4 (20.8) mL/min and in the non-mannitol group from 102.2 (17.8) to 92.3 (23.1) mL/min. CONCLUSIONS: There was a significantly smaller decrease in (51)Cr-EDTA clearance in the mannitol group indicating a nephroprotective effect of mannitol. SAGE Publications 2019-01-07 /pmc/articles/PMC6327333/ /pubmed/30670924 http://dx.doi.org/10.1177/1179554918821320 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Hägerström, Erik
Lindberg, Lotte
Bentzen, Jens
Brødbæk, Kasper
Zerahn, Bo
Kristensen, Bent
The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy
title The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy
title_full The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy
title_fullStr The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy
title_full_unstemmed The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy
title_short The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy
title_sort nephroprotective effect of mannitol in head and neck cancer patients receiving cisplatin therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327333/
https://www.ncbi.nlm.nih.gov/pubmed/30670924
http://dx.doi.org/10.1177/1179554918821320
work_keys_str_mv AT hagerstromerik thenephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT lindberglotte thenephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT bentzenjens thenephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT brødbækkasper thenephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT zerahnbo thenephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT kristensenbent thenephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT hagerstromerik nephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT lindberglotte nephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT bentzenjens nephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT brødbækkasper nephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT zerahnbo nephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy
AT kristensenbent nephroprotectiveeffectofmannitolinheadandneckcancerpatientsreceivingcisplatintherapy